This issue focuses on pathological mechanism analysis, research and development of new treatment strategies, and clinical translation applications, including Zhejiang University’s iCDCs targeted immune regulation therapy to reverse heart failure and cardiac fibrosis, West Lake University’s npegRNA to improve lead editing delivery efficiency, Fudan University’s identification of the key factor KLF5 and its regulatory mechanism for the initiation of lung squamous cell carcinoma, and also covers industry hotspots such as CDE’s inclusion of BRAF V600 mutation targeted innovative drugs in the “Starlight Plan” for children’s anti-tumor treatment. The various achievements not only deepen the scientific understanding of the pathogenesis of diseases, but also provide new targets and technological paths for precise intervention, providing important support for the transformation of basic research in the field of biomedicine and the upgrading of clinical diagnosis and treatment.

---

1、 Western dendritic cells bring new hope for the treatment of heart failure

As a major global health challenge, the pathological core of heart failure lies in progressive cardiac fibrosis and functional decline, and existing treatment methods are difficult to effectively block or reverse this process. On April 8, 2026, Professor Hu Xinyang and Professor Xu Yang’s team from Zhejiang University published a groundbreaking study in the journal Nature, reporting for the first time an engineered immunosuppressive and fibrosis targeted dendritic cell (iCDCs) therapy, providing a new strategy for the treatment of heart failure.

This study confirmed in an animal model of heart failure induced by ischemia and pressure overload that iCDCs can accurately target diseased heart tissue and exert cardioprotective effects through multidimensional and sustained mechanisms. Its core mechanism includes significantly inhibiting pathological immune cell activation, promoting clonal expansion of regulatory T cells (Tregs), thereby effectively reshaping the cardiac immune microenvironment, reducing inflammation and fibrosis deposition. It is worth noting that while this therapy exerts strong local effects, no significant systemic toxic reactions were observed, and its safety performance is outstanding.

The study further validated the therapeutic effect of iCDCs in mouse and non-human primate models. The results showed that after receiving iCDC treatment, the degree of cardiac fibrosis in the model animals was significantly reduced, myocardial perfusion was improved, and cardiac contractile function was substantially enhanced. These data strongly confirm the feasibility and effectiveness of targeted immune regulation in controlling cardiac remodeling from a preclinical perspective.

This study not only establishes lesion targeted immune regulation as a feasible new strategy to combat cardiac fibrosis, but also elevates iCDCs as a highly promising therapeutic platform. Its innovation lies in combining the precise regulation of immune engineering with targeted cardiac pathology, laying a solid theoretical and experimental foundation for the development of next-generation cell therapies that can reverse cardiac remodeling and improve heart failure prognosis. It is expected to promote a fundamental shift in the treatment mode of heart failure from traditional symptom management to pathological correction.

---

2、 Nature Journal Reveals the Dynamic Dual Pathway Mechanism of Neuropeptide Y System Regulating the Decline of Fear Memory

On March 31st, Professor Xu Tianle’s team from Shanghai Jiao Tong University collaborated with Researcher Li Weiguang’s team from Fudan University to publish an important study in Nature Neuroscience. This study systematically elucidated the key role of the neuropeptide Y (NPY) system in the process of fear memory extinction in the ventral CA1 region of the hippocampus (vCA1) and its intricate spatiotemporal regulatory mechanism.

The research team focused on GABAergic interneurons (NPY ⁺ neurons) expressing NPY in the vCA1 region, using male mice that experienced training and fading of cue based fear memories as a model. They found that these neurons regulate memory acquisition and extinction processes through two distinct pathways: rapid GABAergic inhibition and slow NPY mediated inhibition. During the process of fear extinction learning and behavioral state transition, the calcium dynamic activity of NPY ⁺ neurons in the vCA1 region is significantly enhanced, accompanied by an increase in local NPY release levels, indicating that their activity and neuropeptide release are core biomarkers of the extinction process.

Further mechanism analysis indicates that the released NPY regulates the extinction process in a timed and partitioned manner by acting on specific receptors expressed on different subpopulations of neurons. In the early stages of regression, NPY mainly exerts its effects by binding to NPY Y1 receptors; In the late stage of regression, priority is given to activating the NPY Y2 receptor signaling pathway. The temporal conversion of this receptor precisely controls the speed of memory decay and the final degree of consolidation.

The innovation of this study lies in revealing that the fear fading cue preferentially activates the NPY ⁺ interneurons of vCA1, leading to an increase in NPY release. The released NPY acts as a “forked signaling molecule” that simultaneously acts on downstream neuronal clusters expressing different NPY receptors, dynamically regulating the excitation inhibition balance of neural circuits and promoting adaptive switching of fear memory between labile and stable states. This discovery provides a novel cellular and molecular mechanism for understanding how inhibitory neural circuits shift from rapid neurotransmitter release dependent on activity to slow neuropeptide modulation release, thereby regulating complex behavioral state transitions. It also offers potential new targets for intervention strategies in fear related mental disorders such as post-traumatic stress disorder.

---

3、 Fudan University team identifies KLF5 as a key initiating factor for lung squamous cell carcinoma and reveals its mechanism

On April 2nd, Professor Lin Xinhua’s team from Fudan University published an important research result in the renowned oncology journal Cancer Research, systematically elucidating the core role and molecular mechanism of transcription factor KLF5 in the initial stage of lung squamous cell carcinoma (LUSC). This study provides a new theoretical framework for understanding the early occurrence of LUSC and reveals potential therapeutic targets.

KLF5, as a member of the Kr ü ppel like factor family, frequently exhibits genome amplification and abnormal activation in various epithelial derived tumors, including LUSC. However, its specific function and mechanism in the initial transformation from normal epithelial cells to cancer cells have not been clearly defined before. To further investigate the role of KLF5 in tumorigenesis, the research team innovatively constructed a genetically engineered modified organoid model to simulate the carcinogenesis process of normal airway epithelial cells in the human body.

The research results indicate that abnormal activation of KLF5 is a key initiating event driving the transformation of normal airway epithelium to LUSC. During the transformation process, KLF5 plays a core transcriptional regulatory role by extensively reprogramming intracellular biosynthetic and metabolic pathways, triggering a series of characteristic morphological changes and molecular level evolution. Specifically, KLF5 significantly upregulated the expression of genes related to ribosome biosynthesis, enhancing the protein synthesis ability of cells; At the same time, it reshapes the energy metabolism pattern of cells, promotes oxidative phosphorylation processes, and provides sufficient material and energy basis for the rapid proliferation and survival of cancer cells.

Further intervention experiments have confirmed that inhibiting ribosome biosynthesis or blocking oxidative phosphorylation pathways can effectively weaken the malignant progression of LUSC driven by KLF5 activation, which confirms the criticality of the above mechanism. This study not only identified KLF5 as an essential transcriptional regulator in the development of LUSC tumors, but also suggested that KLF5 activated LUSC may exhibit special susceptibility to therapeutic strategies targeting ribosome biosynthesis and oxidative phosphorylation.

In summary, this study not only deepens the understanding of the origin mechanism of LUSC, but more importantly, by identifying the metabolic and synthetic dependence of KLF5 activated tumors, it provides new theoretical basis and potential intervention pathways for the development of precise targeted therapies for this subtype of LUSC.

---

4、 Nat Aging: Aging liver cell-derived extracellular vesicles (EVs) as systemic mediators drive aging associated pan cancer metastasis

On April 3rd, a study published by Wei Congwen’s team at the Military Medical Research Institute in Nature Aging revealed the core role of aging liver cells in this process. Research has shown that extracellular vesicles (EVs) secreted by aging liver cells can serve as key “systemic mediators” that drive distant metastasis of tumors from different tissue sources by delivering specific carcinogenic microRNAs (miRNAs, such as miR-25).

This study confirms that aging liver cells release EVs rich in pro metastatic miRNAs. After entering the circulatory system, these EVs can be taken up by various primary tumor cells. The miRNAs carried by it regulate the signaling network within receptor cells, coordinating and enhancing the invasion and dissemination ability of tumor cells, thereby forming a “systemic microenvironment” favorable for multiple cancer metastases in aging individuals. In animal models, EVs derived from aging liver cells can significantly promote metastasis in young tumor bearing mice; On the contrary, clinical sample analysis also shows that elderly cancer patients have similar EVs and related miRNA features in their bodies.

At the level of translational applications, three potential intervention strategies have been proposed: one is to target aging itself by clearing senescent cells (senolysis); The second is the key regulatory factor P2RX7 that inhibits the secretion of EVs in aging liver cells; The third is to directly silence the relevant pro metastatic miRNAs in EVs. Experimental results have shown that these methods can effectively reduce the tumor metastasis burden in elderly mice.

In summary, this study not only elucidates the molecular mechanism by which aging liver cells systematically drive pan cancer metastasis through the EV miRNA axis, but also provides important theoretical basis and experimental clues for the development of novel intervention strategies for age-related cancer metastasis.

---

5、 The Hong Kong University of Science and Technology reveals the molecular mechanism and new therapeutic targets of primary ciliary dyskinesia caused by RPGR mutations

On March 31st, a research team led by Professor Liu Zhen from the Hong Kong University of Science and Technology published a groundbreaking study in the Journal of Clinical Investigation, which systematically elucidated the key role of GTPase regulatory factor (RPGR) gene variation in the occurrence of primary ciliary dyskinesia (PCD) in retinitis pigmentosa and established a clear “genotype phenotype” association.

Previously, it was known that mutations in the RPGR gene can simultaneously affect the functions of non motor sensory cilia of photoreceptors and active cilia of the respiratory tract, leading to retinitis pigmentosa (RP) and programmed cell death (PCD), respectively. However, the specific RPGR variants that are more likely to drive ciliary motility disorders and trigger PCD, and the underlying cellular biological mechanisms have been unclear.

This study is the first to clarify that the absence or functional defects of RPGR protein specifically disrupt the structural and functional homeostasis of active cilia. The team utilized cutting-edge 2D gas-liquid interface culture organoid models and high-resolution imaging technology to discover that multi ciliated epithelial cells carrying pathogenic RPGR variants exhibit a series of typical ciliary phenotype defects, including significantly reduced ciliary density, abnormally shortened length, and decreased overall pulsation frequency or uncoordinated movement patterns. These defects directly impair the mucus clearance function of the airway, explaining from a pathophysiological perspective why patients experience typical clinical symptoms of PCD such as chronic respiratory infections and bronchiectasis.

At the mechanistic level, research has revealed that RPGR maintains the normal occurrence and coordinated movement of cilia by precisely regulating the dynamic assembly and stability of the cilia base and intracellular F-actin cytoskeleton network. The loss of RPGR function can lead to disruption of F-actin dynamics, thereby disrupting the anchoring and pulsatility coordination of ciliary axons. Of particular importance, the team found through drug screening that interventions targeting abnormalities in this pathway, such as using actin stabilizers, can partially rescue ciliary phenotypes in the model system, providing solid experimental evidence for the development of targeted therapies in the future.

This work not only profoundly reveals the pathogenesis of RPGR related PCD and establishes a phenotype prediction framework based on variant types, but more importantly, opens up new avenues for improving the molecular diagnosis, prognosis evaluation, and patient management strategies of this disease. Meanwhile, the discovery of potential therapeutic targets has brought new hope for the development of pioneering therapies for this type of ciliary disease.

---

6、 Wuhan University team reveals new mechanism of sepsis induced lung injury

The research conducted by Jiang Wanli’s team at Wuhan University, published in Cell Reports in March 2026, systematically elucidated the key role of transcription factor RUNX2 in sepsis induced lung injury. Research has found that under stimulation by lipopolysaccharide (LPS), RUNX2 can transcriptionally activate the expression of the deubiquitinase USP16. The elevation of USP16 specifically removes the ubiquitin chain of mitochondrial iron transporter 2 (MFRN2), disrupts mitochondrial iron homeostasis, and drives iron death in lung epithelial cells, leading to alveolar barrier damage. This effect does not depend on the activation of macrophages. Further research reveals that aromatic hydrocarbon receptors (AHRs) can interact with RUNX2 and inhibit its activity. In animal models, knocking out the Runx2 gene, drug inhibition of USP16, or overexpression of AHR can effectively alleviate lung injury, and the latter two have a synergistic protective effect. This suggests that targeting the RUNX2/USP16/MFRN2 axis or enhancing AHR function is a potential new pathway for intervening in iron death and barrier damage in sepsis induced lung epithelial cells.

This mechanism is consistent with the central role of ferroptosis in sepsis induced lung injury. Iron induced cell death is a form of cell death driven by iron dependent lipid peroxidation, which has been confirmed in various lung injury models. Studies have shown that in sepsis environments, neutrophil extracellular traps (NETs) can exacerbate iron death by modifying m6A methylation of key proteins such as GPX4, while factors such as YAP1 exert inhibitory functions by maintaining iron homeostasis. In addition, the research conducted by Xu Jie’s team at Sun Yat sen University in 2026 provides a supplementary perspective for early damage, discovering that lipid peroxidation directly alters the mechanical properties of cell membranes, increasing their fragility and activating the release of NINJ1 protein mediated damage related molecular patterns (DAMPs), triggering a neutrophil dominated inflammatory storm. This constitutes a vicious cycle of lipid peroxidation membrane physical damage inflammation initiation.

In terms of clinical translation, in addition to targeting molecular targets such as RUNX2, other intervention strategies are also being explored. An earlier study by the same team from Wuhan University found that extracellular vesicles derived from human umbilical vein endothelial cells can effectively suppress sepsis induced inflammatory responses by regulating mitochondrial dynamic balance, demonstrating the potential of cell therapy. At the same time, clinical observation data shows that the level of RUNX2 in the serum of ALI patients caused by sepsis is significantly increased and positively correlated with the severity of the disease and the risk of death, while the level of miR-30a-5p decreases and is negatively correlated with RUNX2. The combination of the two has high predictive value for prognosis. In drug development, the small molecule compound Ferrostatin-1 (Fer-1) has been shown to act as an iron death inhibitor and exert lung protective effects in early sepsis by inhibiting lipid peroxidation, stabilizing cell membranes, and reducing inflammation through multiple mechanisms. In addition, various active ingredients in traditional Chinese medicine, such as Salicroside and rutin, have been found to inhibit ferroptosis by activating antioxidant pathways such as Nrf2/SLC7A11/GPX4, providing new ideas for integrated traditional Chinese and Western medicine treatment.

In summary, current research has deepened our understanding of the mechanism of sepsis induced lung injury from multiple perspectives, including transcriptional regulation, cell death patterns, membrane biomechanics, and clinical biomarkers. Among them, the RUNX2/USP16/MFRN2 axis driven epithelial cell ferroptosis is a newly revealed key pathway. Future treatment strategies are expected to integrate multi-target interventions targeting iron death, membrane stability, and inflammatory storms, combined with novel therapeutic carriers such as exosomes, to more effectively block disease progression and improve patient prognosis.

---

7、 Pancreatic cancer resists iron death through hypoxia microenvironment, new research reveals the mechanism

Pancreatic ductal adenocarcinoma (PDAC) is known as the “cancer king” due to its strong invasiveness and poor prognosis, with a five-year survival rate of less than 10%. Although most PDACs carry carcinogenic KRAS mutations, which should theoretically make them sensitive to iron death (a new form of cell death driven by iron dependent lipid peroxidation), clinical observations show that pancreatic cancer is significantly resistant to iron death induction. Recently, research published in Mol Cell by institutions such as the Ludwig Cancer Institute has revealed in depth the microenvironment driving mechanisms behind this resistance.

Research has found that the unique interstitial microenvironment of pancreatic tumors is key to resisting ferroptosis. In this environment, not only is there severe hypoxia, but the metabolite composition of the interstitial fluid is also significantly different from other tumors. These two factors do not act independently, but work together to build a powerful ‘protective umbrella’ for cancer cells. The research team placed PDAC cells in a culture medium that simulated the hypoxia and special nutritional conditions (such as a formula rich in cysteine and lacking glutamine), and found that their resistance to iron death was significantly enhanced. The core regulator of this process is hypoxia inducible factor 2 (HIF-2 α), rather than its homologous factor HIF-1 α.

It is noteworthy that the role of HIF-2 α in PDAC is completely opposite to that in renal cell carcinoma. In renal cancer, HIF-2 α typically promotes tumor growth; In this study, researchers initially hypothesized that hypoxic PDAC cells with high expression of HIF-2 α would be sensitive to ferroptosis, but the experimental results showed that they dominated a powerful cell protection program. In terms of specific mechanisms, HIF-2 α significantly enhances the biosynthesis ability of intracellular glutathione (an important antioxidant) by upregulating cysteine/glutamate reverse transporters (such as xCT) and key enzymes in the glutathione synthesis pathway through transcription. Meanwhile, HIF-2 α also induces mitochondrial autophagy, clearing damaged mitochondria and reducing the production of reactive oxygen species from the source, jointly maintaining the cellular redox homeostasis and resisting lipid peroxidation accumulation.

This study not only clarifies how the microenvironment of pancreatic cancer “shapes” its unique metabolic vulnerability and drug resistance phenotype, but also points out that HIF-2 α is the core hub connecting hypoxia, metabolic reprogramming and iron death defense. It suggests that future treatment strategies for PDAC may need to go beyond single KRAS pathway inhibition and instead develop drugs targeting the downstream specific protective pathway of HIF-2 α, or adopt a combination therapy that simultaneously attacks carcinogenic KRAS signaling and HIF-2-mediated survival barrier, providing new theoretical basis and potential intervention directions for conquering this “cancer king”.

---

8、 The team from Xihu University has developed a new type of pegRNA, breaking through the bottleneck of gene editing delivery efficiency

On April 7th, the team led by Song Chunqing from Westlake University published a study in Nature Biomedical Engineering. Prime Editing (PE), as an advanced technology that enables precise gene replacement, insertion, or deletion, has broad prospects in the field of gene therapy. However, the low delivery efficiency of its core delivery form, the PE ribonucleoprotein complex, severely restricts its clinical application and translation.

To address this bottleneck, the team innovatively designed a non classical pegRNA structure. Unlike traditional pegRNA, which places reverse transcription templates and primer binding sequences at the 3 ‘end of sgRNA, npegRNA cleverly integrates the RTT-PBS functional module into the stem loop structure of sgRNA. This structural recombination significantly improves the stability of pegRNA and the overall efficiency of the editing system without introducing additional genetic elements or increasing the risk of off target editing.

Experimental data shows that npegRNAs exhibit excellent performance when using PE RNP for transient delivery: their average editing yield is up to 26.8 times higher than standard pegRNAs, and they also achieve a 5.9-fold improvement compared to previously reported engineering optimized pegRNAs. It is particularly crucial that in experiments simulating the installation of disease-related pathogenic mutations in human cell lines, npegRNA increased editing efficiency by 123 times, fully demonstrating its enormous potential to address practical therapeutic pain points.

This study not only provides an efficient and stable novel pegRNA design paradigm, but also paves the way for lead editing technology to move from laboratory to clinical use, especially for in vivo treatment of genetic diseases, as it is fully compatible with the preferred RNP and RNA delivery systems for clinical translation.

---

9、 East China Normal University team reveals REV-ERB α agonist can break through the ‘treatment time window’ of pulmonary arterial hypertension

On April 2nd, Professor Chen Lihong’s team from East China Normal University published important research results in Nature Communications, systematically elucidating the key role and therapeutic potential of nuclear receptor REV-ERB α in the pathological process of pulmonary arterial hypertension (PAH). PAH is a fatal metabolic vascular disease characterized by progressive increase in pulmonary vascular resistance and right heart failure. Existing therapies are mostly limited to symptom relief and disease delay, and have limited efficacy for patients who have entered the late stage of structural remodeling. There is a significant “treatment time window” bottleneck.
This study comprehensively utilizes a genetically engineered mouse model and pharmacological intervention methods to clarify for the first time the differential role of REV-ERB α/β, a core circadian rhythm regulatory factor, in PAH. Research has found that specific deletion of the Rev erb α gene significantly exacerbates the pathological phenotype of PAH induced by hypoxia or monocrotaline, including more severe pulmonary vascular remodeling and right ventricular hypertrophy; On the contrary, activation by agonist drugs or overexpression of REV-ERB α gene can effectively alleviate disease progression. It is worth noting that the knockout of Rev eb β did not have a significant effect, indicating that REV-ERB α has a unique and irreplaceable function in PAH regulation.

The breakthrough finding of the study is that even in the late stages of PAH disease where PAH has been fully established, administering REV-ERB α – specific agonists can significantly reverse the formed pulmonary vascular lesions, improve hemodynamics and cardiac function. This indicates that targeting REV-ERB α may break through the “time window” limitations of traditional PAH treatment and provide new intervention hope for advanced patients.

---

10、 Wu Hao’s team from Shanghai Jiao Tong University published a study on single-cell atlas of cochlear nucleus in Cell Research

On April 6th, Professor Wu Hao’s team from the School of Medicine at Shanghai Jiao Tong University published a research paper titled “Single cell and spatial transcriptomic atlas of the mouse cochlear nucleus reveals region specific cell types and plasticity in hearing loss” in Cell Research (IF: 46.351). This study integrated mononuclear RNA sequencing (snRNA seq) with high-resolution single-cell spatial transcriptome technology to systematically map the whole cell type of the mouse cochlear nucleus (CN) for the first time, and deeply analyzed its molecular and spatial recombination mechanisms in a model of congenital hearing loss, providing a key theoretical basis and potential intervention targets for auditory center repair.
The cochlear nucleus, as the primary central relay station of the auditory pathway, receives all acoustic information input from the inner hair cells. Its fine cellular composition and loop structure are the anatomical basis for the initial processing, diversion, and forwarding of auditory signals, as well as the core target area for auditory brain computer interface and neural regeneration therapy. However, the cellular diversity, molecular characteristics, and dynamic changes of CN in hearing loss have not been systematically elucidated for a long time. The Wu Hao team identified dozens of cell subtypes, including excitatory projection neurons, inhibitory interneurons, and glial cells, through large-scale single-cell transcriptome sequencing of adult mouse CN tissues. They further accurately localized them to subregions such as the ventral cochlear nucleus (VCN) and dorsal cochlear nucleus (DCN) of CN using spatial transcriptome technology, revealing a strict correspondence between cell types and anatomical functional domains.

Further research compared the transcriptome differences of CN in mice with congenital hearing loss model and normal hearing mice, and found that hearing loss can cause significant reprogramming of gene expression profiles of multiple cell types in CN, including abnormal activation of synaptic plasticity related pathways and neuroinflammatory response pathways in excitatory neuronal groups. Of particular importance, the team identified a subtype of plexus cells (Spp1+plexus cells) that specifically express Secreted Phosphoprotein 1 (Spp1). This cell subset showed a significant upregulation of Spp1 expression and a significant change in its spatial distribution after hearing loss. Through gene knockout experiments, it has been confirmed that the loss of Spp1 leads to a decrease in the coding ability of mouse cochlear nucleus neurons for sound stimuli, indicating that Spp1 plays a key role in maintaining CN auditory signal processing function and may become a molecular target for intervening in central remodeling after hearing loss.

This study not only constructed the first comprehensive and high-precision single-cell and spatial transcriptome atlas resource of the cochlear nucleus, providing an important cellular and molecular database for auditory neuroscience research, but also revealed the plasticity changes of CN under hearing loss conditions from a systems biology perspective. The discovered Spp1+cell subtypes and their functions provide new theoretical basis and intervention directions for the development of functional reconstruction strategies targeting the auditory central pathway and the search for therapeutic targets for restoring or compensating hearing.

---

11、 The Center for Drug Evaluation (CDE) of the National Medical Products Administration has included Hisilicon Pharma HSK42360 tablets in the “Starlight Plan”

On April 8th, the Center for Drug Evaluation (CDE) of the National Medical Products Administration officially announced on its official website that HSK42360, a Class 1 innovative drug declared by Hisilicon Pharmaceutical Group Co., Ltd., will be included in the “Children’s Anti Tumor Drug R&D Encouragement Pilot Program” (commonly known as the “Starlight Program” in the industry). This measure marks the national level policy support and resource allocation for the research and development of the drug in the field of pediatric oncology, aiming to accelerate its clinical development and marketing process for specific indications in children.
According to the announcement, HSK42360 tablets are included in the “Starlight Plan” for the development of pediatric indications: for the treatment of recurrent or progressive gliomas carrying BRAF V600 mutations. Glioma is one of the most common solid tumors of the central nervous system in children, with some high-grade or recurrent/progressive cases having extremely poor prognosis and a huge unmet clinical demand. The BRAF V600 mutation is an important driver gene mutation in this type of tumor, and precise treatment targeting this target has become an international frontier research direction. HSK42360, as an oral small molecule inhibitor targeting this mutation, has shown potential therapeutic effects in adult research data. This shift towards pediatric indication development aims to provide new and more targeted treatment options for this specific patient population.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.